Fundraising FoxDCVC Bio — 2023 Investments
6 investments dated 2023 · listed companies and verified rows first · show all
Empirico is a San Diego-based clinical-stage biotech that uses human genetics data and computational methods to discover disease targets and develop siRNA and antibody therapeutics.
BiotechSan Diego, US
Omri Gottesman(Executive Officer, Director)inShannon Bruse(Executive Officer, Director)inBrian Cajes(Executive Officer)in
BoardKolluri Swaroop(Director)
Board seatJohn Hamer· per SEC Form D · $55.2M raise · filed Mar 2023
Co-investorsDCVC (Data Collective)Felicis VenturesQiming Venture Partners USAQiming Venture Partners
MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.
BiotechCircular EconomyNew MaterialsEmeryville, US
Philip Ross(Founder)inMichael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)inEddie Pavlu(Founder)Phil Ross(Founder)Sophia Wang(Founder)
Board seatKiersten Stead· per SEC Form D
Co-investorsATEL VenturesDCVC (Data Collective)GaingelsHemisphere Ventures LLCSOSVValor Equity Partners+9 more
__Twitter.png)
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life Sciences5AM VenturesFrazier Healthcare PartnersWestlake Village BioPartners
Totus Medicines is a biopharmaceutical company developing small molecule drugs to address untreatable diseases by combining approaches in molecular design, structural biology, genetics, and cell biology.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Neil Dhawan, PhD(Co-Founder)Nassim Usman, PhD(CEO and President)
Co-investorsDCVC (Data Collective)Social Impact Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ascend Gene & Cell TherapiesSolu Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.